Publication: Pre-analytical modification of serum mirnas: Diagnostic reliability of serum mirnas in hemolytic diseases
Issued Date
2021-11-01
Resource Type
ISSN
20770383
Other identifier(s)
2-s2.0-85117890064
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Clinical Medicine. Vol.10, No.21 (2021)
Suggested Citation
Yukichi Takada, Tatsuki Shibuta, Mayu Hatano, Kenichi Sato, Mari Koga, Ayaka Ishibashi, Tetsuhiro Harada, Takashi Hisatomi, Hanae Shimura, Noriyasu Fukushima, Kamonlak Leecharoenkiat, Supat Chamnanchanunt, Saovaros Svasti, Suthat Fucharoen, Tsukuru Umemura Pre-analytical modification of serum mirnas: Diagnostic reliability of serum mirnas in hemolytic diseases. Journal of Clinical Medicine. Vol.10, No.21 (2021). doi:10.3390/jcm10215045 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/77716
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Pre-analytical modification of serum mirnas: Diagnostic reliability of serum mirnas in hemolytic diseases
Abstract
Circulating microRNAs (miRNAs) are useful biomarkers of hemolysis. Since blood cells are the main origins of circulating miRNAs, we evaluated blood cell-related pre-analytical modification of the miRNA signatures during blood drawing and serum processing. The levels of miRNA before and after ex vivo blood drawing were analyzed with the reverse transcriptase-based poly-merase chain reaction method. Furthermore, the changes of miRNA signatures caused by different time-lag between blood drawing and serum preparation by 24 h were evaluated. Finally, we compared the miRNA levels between leftover samples and samples of hemolytic diseases. Blood drawing procedure induced increments of red blood cell (RBC)-related miRNAs (miR-451a, miR-486) about 2-fold. One hour standing of blood samples before serum separation induced almost the same increases in RBC-related miRNAs. To test the clinical usefulness of miR-451a as a biomarker of he-molytic diseases, we analyzed miRNAs of samples from 10 normal subjects, 30 leftover samples in the clinical laboratory, and 20 samples from patients with hemolytic diseases. Serum miR-451a significantly increased in patients with hemolytic anemia more than the levels of pre-analytical modi-fication. In conclusion, the pre-analytical modification of serum miRNAs did not disturb the usefulness of RBC-derived miRNAs as biomarkers of hemolytic diseases.